Navigation Links
Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Date:6/12/2013

umab

Brodalumab is a highly-selective human monoclonal antibody that binds to and blocks signaling via the IL-17 receptor. The IL-17 pathway plays an important role in inducing and promoting inflammatory disease processes. 

Brodalumab is the first investigational treatment in development that blocks the IL-17 receptor, thereby blocking several of the IL-17 ligands at once. By stopping IL-17 ligands from binding to the receptor, brodalumab prevents the body from receiving signals that may lead to inflammation and other ailments. At this time, other agents in development seek to target a single IL-17 ligand. 

In addition to psoratic arthritis, brodalumab is currently being investigated for the treatment of psoriasis (Phase 3) and asthma (Phase 2).

About Psoriatic Arthritis

Psoriatic arthritis is a chronic disease of the immune system that causes joint pain, stiffness and swelling which can become progressively worse over time, and may also include red patches of skin topped with silvery scales.1

The progressive joint damage, pain and swelling coupled with painful, scaly, red skin patches can disrupt a person's ability to perform daily activities, such as using their hands, standing for long periods or walking.2 Psoriatic arthritis affects 30 to 50 percent3 of the approximate 125 million people worldwide who have psoriasis.4 

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping people around the world in the fight against serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to drama
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Calif. , April 20, 2015  Ardelyx, ... company focused on cardio-renal, gastrointestinal and metabolic diseases, ... MRCP, has joined the Company,s Board of Directors. ... and board level experience, having built and led ... development, regulatory approval and into healthcare systems globally. ...
(Date:4/20/2015)... INDIANAPOLIS , April 20, 2015  Eli Lilly ... stage data from several targeted cancer therapies, reflecting Lilly,s ... Research (AACR) Annual Meeting 2015, held April 18-22 in ... "Bringing Cancer Discoveries to Patients" is the theme of ... through Lilly,s commitment to broadening its portfolio of therapies ...
(Date:4/20/2015)... - Development of a Novel ... VOLVOX Platform - To be Presented on Tuesday, Apr ... Assembly of Antibody-drug Conjugates Using an anti-HER2 Monoclonal Antibody ... Apr 19, 1:00 PM EST Invictus Oncology ... announced that the company,s novel computational platform technology (VOLVOX) ...
(Date:4/20/2015)... BEIJING, April 20, 2015 Sinovac Biotech Ltd. ... China, today announced its unaudited financial results for the ... Fourth Quarter 2014 Financial Highlights(Compared to the ... $20.3 million, a decrease of 11.4% from $22.9 million ... the stockpiling of H5N1 pandemic influenza vaccine of $0.1 ...
Breaking Biology Technology:Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6Invictus Oncology Announces Two Posters to be Presented Describing its Platform Technology on Supramolecular Therapeutics at the American Association for Cancer Research Annual Meeting, 2015 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18
... ISELIN, N.J., Sept. 12 SyntheMed, Inc. ... will host a symposium,entitled "Post-Operative Adhesions in ... next week,s European Association for,Cardio- Thoracic Surgery ... be chaired by Professor Stephen Westaby of ...
... Sept. 12 Two new white papers ... free download from,Microtest ( http://www.microtestlabs.com ). The ... device manufacturers and one which is specialized,for ... associated with sterility testing and reviews different ...
... 12 Prolog Ventures, a venture capital,firm specializing ... has joined the firm as its fourth partner. ... early-stage investing, venture fund,management, and technology commercialization. ... director at Mason,Wells in Milwaukee, WI, where he ...
Cached Biology Technology:SyntheMed to Host Symposium on Adhesions in Cardiac Surgery 2Free White Papers Detail Sterility Testing Essentials for Medical Device, Pharmaceutical Manufacturers 2Dan Broderick Joins Prolog Ventures as Partner 2Dan Broderick Joins Prolog Ventures as Partner 3
(Date:3/31/2015)... March 31, 2015  Elephant Talk Communications Corp. (NYSE ... provider of Software Defined Network Architecture (ET Software DNA® ... revenue of approximately $20.4 million for the year ended ... million for the year ended December 31, 2013. ... Company had completed its multi-year transition away from its ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ... Biometrics - Global Strategic Business Report" report to their offering. ... Voice Biometrics in US$ Thousands by the following Segments: Face Biometrics, ... US, Canada , Japan , ... Middle East & Africa , ...
(Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... October 17, 2011 The Peggy Lillis Memorial ... and Senior Vice President of Optimer Pharmaceuticals, Inc. and ... Tufts University, with an achievement award to recognize his ... new treatments for Clostridium difficile infection (CDI) ...
... -- October 17, 2011-- In a paper published today in ... Mary R. Loeken, PhD, has identified the enzyme AMP kinase (AMPK) ... of neural tube defects such as spina bifida and some heart ... if women with diabetes -- either type 1 or type 2 ...
... occurs naturally in bacteria as Ralstonia eutropha ... biodegradable and is not dependent on fossil resources, this ... replace petroleum-based plastics. New research reported in BioMed Central,s ... an alternative method of producing PHB in microalgae. ...
Cached Biology News:Peggy Lillis Foundation honors Dr. Sherwood Gorbach for career combating C. diff infection 2Peggy Lillis Foundation honors Dr. Sherwood Gorbach for career combating C. diff infection 3Joslin study finds clue to birth defects in babies of mothers with diabetes 2
... is portable, easy-to-use and makes identifying your samples ... Easy to use Labels withstand extreme ... sizes Time/Date stamp Laboratory ... Serialization feature makes you more efficient ...
Each 72-well MiniTray is low profile, with lid. Conical well shape, 10 l....
...
...
Biology Products: